Bolder Cures Act Could Ease Limits On Drug Cost Claims
A brief section in the fast-evolving 21st Century Cures Act would modestly loosen U.S. Food and Drug Administration restrictions on drugmaker claims of cost-effectiveness but will only provide significant cover from...To view the full article, register now.
Already a subscriber? Click here to view full article